InvestorsHub Logo
Followers 1
Posts 70
Boards Moderated 0
Alias Born 03/12/2019

Re: None

Wednesday, 10/26/2022 5:38:55 PM

Wednesday, October 26, 2022 5:38:55 PM

Post# of 869
Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/433/matinas-biopharma-announces-positive-interim-data-from-the
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MTNB News